Through systematic evaluation of their clinical development potential, we demonstrate that Etanercept and Asciminib hydrochloride may represent effective therapeutic agents for NRDS through their activation of LTBR. The gene discussed is LTBR; the disease is newborn respiratory distress syndrome.